Susan B. Mikell
New technologies delivered to your inbox Subscribe
2014-321 – TGR5 antagonist for the treatment of cholangiopathies including polycystic liver disease.
2014-102 – The device harvests a small strip of rectus fascia (1 x 5 cm) by simultaneously dilating the rectus fascial, stapling and then cutting the fascia. The device is small enough to fit through a 3-5 cm lower abdominal incision and articulates to an adjustable angle to account for possible patient obesity.
2010-196 – iPhil mouse line permitting inducible loss of eosinophils to study eosinophil-related diseases. Genotype/Phenotype: Inducible ablation of eosinophils is accomplished through expression of the human diptheria toxin receptor exclusively in cells of the eosinophil lineage. Diptheria toxin exposure completely eliminates circulating osinophils without affecting other cell types. Depletion is... Read More
2013-105 – The ε4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD) compared to the more common ε3 allele. Studies in animal models and humans suggest that apoE4 exhibits both loss-of-function and gain-of-toxic-function compared to apoE3. In regulating amyloid pathology, apoE4 is less efficient than apoE3 in mediating the clearance of... Read More
2012-150 – Patients who develop obstruction in the gastrointestinal track due to inflammatory strictures, or failure of sphincter muscles to relax, are benefitted by relief of that obstruction. Mayo has developed a device to stabilize the position and control length and depth. The device can be used in an lumen (gastrointestinal, vascular, urologic, gynecologic, pulmonary etc).
2012-051 – The Weighted Deaver Retractor was designed in response to surgeon and patient needs for a more ergonomic and efficient tool to be used during gynecological or urological surgery. The current deaver retractor on the market now requires a surgical assistant to grasp and retract to allow for increased visibility for the surgeon. Presently, the deaver retractor being used today cannot hold... Read More
2009-300 – An endoscopic vessel harvesting device/modification will allow for independent fixation of vessel branches during the harvesting process, and thereby minimizing vessel shrinkage during vessel cauterization. This device/modification will also redirect vessel tension away from the origin of the primary vessel during the harvesting process. This redirection of stress forces along the vessel... Read More
2009-296 – Mouse model of recessive polycystic Kidney Disease (ARPKD)
2009-139 – Technology Description Mayo Clinic researchers have exploited normal blood-brain barrier (BBB) transport mechanisms utilized by apolipoproteins to deliver agents across the BBB and have designed peptides incorporating apolipoprotein LDL receptor binding sequences. These peptides contain additional amino acid sequences to facilitate the binding and delivery of various biological and chemical... Read More
2009-131 – CD2 Binding Agents for Decreasing Suppressive Monocytes in Cancer and Sepsis CD2 binding molecules, such as alefacept, have been shown to deplete immunosuppressive monocytes (e.g., CD14+/DR- or CD14+/DRlow) in patients with lymphoma. Increased levels of immunosuppressive monocytes have been found to be associated with poor prognosis. Continued depletion of immunosuppressive monocytes appeared... Read More
2009-107 – A device which allows for rapid cleaning of the colon in preparation for colon examination by an endoscope or other imaging methods such as CT or MR colonography. The device is aimed at facilitating colonic lavage to allow either minimal prep, or no prep prior to colonoscopy.
2007-012 – Technology Description The past 20 years have witnessed an unprecedented increase in eosinophil-associated diseases such as allergy, asthma, and inflammatory gastrointestinal syndromes. Despite this rise in the need for an eosinophil-specific assay few reagents are available. Mayo Clinic researchers have developed a unique monoclonal antibody reactive to the eosinophil specific protein... Read More
2006-224 – This is to provide knowledge about the use of neurotensin receptor agonists for treatment of various medical problems, including acute and chronic pain due to various causes and abuse of various types of psychostimulants (such as nicotine, cocaine, and amphetamines).
2006-154 – To increase progranulin in animals, progranulin levels and biologically active fragments of progranulin can be elevated in animals by direct administration of the protein or its fragments, either in the presence or absence of agents that stabilize the biological activity. Routes of delivery include, but are not limited to, intranasal, oral, inhalation, intracerebro-ventricular injection,... Read More
Fluorescent In Situ Hybridization (FISH) Probe Development to Detect Immunoglobulin Light Chains Kapa (IGK) and Lambda (IGL) Translocations
2005-072 – Lymphoma, the cancer to the lymph glands and lymphocytes develop as a consequence of acquired genetic/chromosomal changes. In clinical practice identification of these genetic changes are critical in diagnosis and treatment of lymphoma patient. We have developed fluorescent in situ hybridization (FISH) for two targets frequently involved in lymphoma development. We believe that these probes... Read More
2004-291 – Technology Description Pathogenic mutations of the Leucine-Rich Repeat Kinase 2 (LRRK2) enzyme are recognized as the most frequent genetic cause of both familial and sporadic parkinsonism. Mayo Clinic researchers were the first to identify this association and have gone on to develop an in-depth understanding of LRRK2 function as well as numerous tools to help identify therapeutic agents to... Read More
2004-185 – Discovery of the genetic cause of clinical, late-onset (typical) Parkinson’s disease in multiple families with an autosomal pattern of disease inheritance. Six coding mutations have now been identified within eight families, in a novel gene that is comprised of 61 exons (alternately spliced) that encodes a protein of ~280kD. The gene is located on chromosome 12p11.2-q13.1 and is responsible... Read More
In vivo Visualization of Alzheimer's Amyloid Plaques by MRI in Transgenic Mice without a Contrast Agent
2004-139 – One of the cardinal pathologic features of Alzheimer’s disease (AD) is formation of senile or amyloid, plaques. Transgenic mice have been developed that express one or more of the genes responsible for familial AD in humans. Doubly transgenic mice develop “human-like” plaques, providing a mechanism to study amyloid plaque biology in a controlled manner. Imaging of labeled plaques has been... Read More
2003-149 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More
2001-127 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More
2000-025 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More